(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.(b)(4).It is indicated that the device is not returning for evaluation; therefore, a failure analysis of the complaint device could not be completed.The investigation was unable to determine a conclusive cause for the reported patient effects.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.It should be noted that the reported patient effects of stenosis and claudication are known potential patient effects as listed in the supera instructions for use (ifu).Although a conclusive cause for the reported patient effects and the relationship to the product, if any, cannot be determined, there is no indication the reported patient effects were caused by or related to the design, manufacture or labeling of the device.
|
On (b)(6) 2014, a supera stent was implanted in a superficial femoral artery (sfa), chronically occluded lesion, without reported issue.Post implantation angiography was unable to be performed due to the patients agitated state.On (b)(6) 2015, the patient experienced disabling claudication and was hospitalized for in stent re-stenosis.Balloon angioplasty was performed as treatment.Reportedly, the patient is in ok condition with good results.There was no additional information provided.
|